Jason Matuszewski, CEO and Chairman of the Board at BioStem Technologies (OTC: BSEM), has been named a 2025 Florida Award winner by Ernst & Young's prestigious Entrepreneur of The Year® program.
This underlines BSEM's growing market share and competitive edge in a multibillion-dollar segment of the healthcare market, affirming that the company is a real player in MedTech, not just a speculative story!
BioStem Technologies (OTC: BSEM) CEO Jason Matuszewski has been recognized as one of the top entrepreneurial honors in the country by Ernst & Young. The award celebrates Matuszewski's vision, impact, and exceptional leadership in guiding BioStem to the forefront of regenerative medicine.
Based in Pompano Beach, Florida, BSEM is a trailblazing MedTech company dedicated to healing chronic, non-healing wounds through its proprietary BioREtain® technology. The company's placental-derived allografts are trusted by clinicians nationwide to meet the rising demand for advanced wound care. With a mission rooted in science, innovation, and patient-first values, BSEM has become a high-growth leader redefining what's possible in regenerative therapies.
This award win is very good news for BSEM for several reasons, both tangible and strategic. It validates leadership and vision. Being named Entrepreneur of The Year® is one of the most prestigious recognitions in business leadership. It signals that Jason Matuszewski's leadership is credible, visionary, and results-driven, which boosts investor confidence in BioStem's long-term strategy and execution.
It also puts BSEM in the national spotlight, exposing it to a larger network of potential institutional investors, strategic partners, and analysts. The award acknowledges not just the CEO, but the innovation and success of BioStem's core technology-BioREtain®-and its effectiveness in addressing chronic wound care. a regional winner, Matuszewski now advances to the national Entrepreneur of The Year® competition this fall, with a chance to represent the U.S. on the global stage in 2026.
BSEM's revenues skyrocketing, game-changing partnerships, a potential NASDAQ listing, as well as a Zack's Small Cap Research price target of $35.50, all amplify why the stock should be high on your radar.
Discover why BSEM is a high-growth opportunity backed by proven leadership.

This message is a paid advertisement for BioStem Technologies Inc. (OTC: BSEM) from Sideways Frequency and Huge Alerts. It's Today Media, LLC. receives a fixed fee for each subscriber that clicks on a link in this email, totaling up to $5,150.00. Other than the compensation received for this advertisement sent to subscribers, It's Today Media and its principals are not affiliated with either Sideways Frequency or Huge Alerts. It's Today Media and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither It's Today Media nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from It's Today Media to buy or sell any security. It's Today Media has not evaluated the accuracy of any claims made in this advertisement. It's Today Media recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding BioStem Technologies Inc. (OTC: BSEM) on Huge Alerts' website for additional information about the relationship between Huge Alerts and BioStem Technologies Inc. (OTC: BSEM).